PHAS - PhaseBio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

PhaseBio Pharmaceuticals, Inc.

1 Great Valley Parkway
Suite 30
Malvern, PA 19355
United States
610-981-6500
http://www.phasebio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees32

Key Executives

NameTitlePayExercisedYear Born
Mr. Jonathan P. MowPres, CEO & Director561.1kN/A1965
Mr. John P. SharpChief Financial Officer451.62kN/A1965
Dr. John S. LeeChief Medical Officer473.43kN/A1968
Mr. Kristopher L. HansonVP & Head of LegalN/AN/AN/A
Mr. Michael B. YorkVP of Corp. Devel. & Commercial StrategyN/AN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Corporate Governance

PhaseBio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.